indazoles has been researched along with Hypogonadism in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Park, J; Tanaka, H; Wada, M | 1 |
| Bondarenko, A; Borisov, P; Tishova, Y; Tsimafeyeu, I; Zakurdaeva, K; Zukov, R | 1 |
| Albersen, M; Bastin, J; Bechter, O; Beuselinck, B; Clement, P; Decallonne, B; Dumez, H; Lerut, E; Oyen, R; Punie, K; Schöffski, P; Vanderschueren, D; Verbiest, A; Werbrouck, E; Wildiers, H; Woei-A-Jin, FJ; Wolter, P | 1 |
1 trial(s) available for indazoles and Hypogonadism
| Article | Year |
|---|---|
Testosterone for Managing Treatment-related Fatigue in Patients With Metastatic Renal Cell Carcinoma: A Phase 2 Randomized Study FARETES.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Fatigue; Follow-Up Studies; Humans; Hypogonadism; Indazoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Quality of Life; Sulfonamides; Sunitinib; Testosterone | 2021 |
2 other study(ies) available for indazoles and Hypogonadism
| Article | Year |
|---|---|
HASPIN kinase inhibitor CHR-6494 suppresses intestinal polyp development, cachexia, and hypogonadism in Apcmin/+ mice.
Topics: Adenomatous Polyposis Coli Protein; Animals; Cachexia; Female; Hypogonadism; Indazoles; Intestinal Neoplasms; Intestinal Polyps; Intracellular Signaling Peptides and Proteins; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Protein Serine-Threonine Kinases; Pyridazines | 2020 |
Prospective evaluation of hypogonadism in male metastatic renal cell carcinoma patients treated with targeted therapies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cross-Sectional Studies; Humans; Hypogonadism; Indazoles; Kidney Neoplasms; Luteinizing Hormone; Male; Middle Aged; Molecular Targeted Therapy; Prevalence; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Sirolimus; Sulfonamides; Sunitinib; Testosterone; Vascular Endothelial Growth Factor A | 2019 |